Clinical Trial Update: Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial update on agomelatine for major depressive disorder focusing on efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Agomelatine (agomelatine)

Snippet

Sponsor: Novartis | Conditions: Major Depressive Disorder (MDD) | Phase 3 | Status: COMPLETED